Veru Inc
NASDAQ:VERU
Veru Inc
Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. The company is headquartered in Miami, Florida and currently employs 252 full-time employees. The firm is focused on developing medicines for the management of breast and prostate cancers. The firm's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. The company has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
Veru, Inc. is an oncology biopharmaceutical company, which engages in developing novel medicines for the management of prostate cancer and breast cancer. The company is headquartered in Miami, Florida and currently employs 252 full-time employees. The firm is focused on developing medicines for the management of breast and prostate cancers. The firm's FC2 segment consists of its commercial product, FC2. The Pharmaceuticals segment includes activities related to multiple drug products under clinical development and ENTADFI, a treatment for benign prostatic hyperplasia. The company has a commercial Sexual Health Division, which includes two products, such as ENTADFI, a treatment for benign prostatic hyperplasia (BPH), and the FC2 Female Condom (Internal Condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.
Net Loss: Veru reported a net loss of $5.3 million ($0.26 per diluted share), an improvement from a $8.9 million loss in the prior year’s quarter.
Cost Reductions: Research and development expenses dropped to $1.3 million from $5.7 million, and general and administrative expenses fell to $4.1 million from $5.2 million.
Capital Raise: The company raised $23.4 million in net proceeds from a public offering in October 2025, boosting its cash position.
Cash Position: Cash, cash equivalents, and restricted cash rose to $33 million as of December 31, 2025, up from $15.8 million at the end of September.
Clinical Update: Veru outlined plans for its Phase IIb PLATEAU obesity study, set to begin this quarter, with interim results expected in Q1 2027.
Regulatory Progress: The FDA provided clarity on two potential approval pathways for enobosarm/GLP-1 therapy; preservation of lean mass and improved physical function could be sufficient if incremental weight loss is less than 5%.
